Inhibiting microglial activation stands out as a potential strategy for treating neurological diseases associated with neuroinflammation
Overall Wellness Improves energy, reduces fatigue, and promotes better skin from within

BPC-157 Human Clinical Trials Status (2025-2026) Only 3 published human studies exist as of March 2026all pilot studies with small sample sizes The largest trial was cancelled : A 2015 Phase I study with 42 volunteers never published results Total human subjects studied : Fewer than 30 people across all published trials No randomized controlled trials : All existing studies lack placebo controls What the Human Studies Show Interstitial cystitis (2024) : 12 patients, 80-100% symptom resolution with bladder injections Knee pain (2021) : 16 patients, 87.5% reported significant relief at 6-12 months IV safety (2025) : 2 adults tolerated up to 20mg IV with no adverse effects Regulatory Reality FDA Category 2 (2023): Cannot be legally compounded due to insufficient safety data WADA prohibited (2022): Banned under S0 Unapproved Substances for all athletes Not approved anywhere : No regulatory agency worldwide has approved BPC-157 for human use The Gap Between Animal and Human Research If youve read about BPC-157 online, youve likely encountered impressive claims: accelerated tendon healing, gut repair, nerve regeneration, and more

Research shows that GHK-Cu activates several pathways involved in tissue repair and regeneration: Stimulating keratinocytes and fibroblasts Keratinocytes form the outer layer of skin, and GHK-Cu stimulates these cells to proliferate and migrate to the site of damage, speeding up the healing of acne lesions
However, its essential to approach MIC injections as a supplementary measure theyre often most effective when combined with a balanced diet and consistent exercise
Statements have not been evaluated by the FDA or any regulatory authority